###
中国临床研究:2025,38(11):1634-1638,1642
本文二维码信息
码上扫一扫!
脓毒症相关急性肾损伤的治疗进展
(1. 山西医科大学第五临床医学院, 山西 太原 030012;2. 山西医科大学第一医院, 山西 太原 030001;3. 山西省中西医结合医院, 山西 太原 030013)
Progress in the treatment of sepsis⁃associated acute kidney injury
摘要
本文已被:浏览 182次   下载 112
投稿时间:2024-11-09   网络发布日期:2025-11-26
中文摘要: 脓毒症相关急性肾损伤(SA-AKI)是住院患者常见的危重症,具有发病率高、死亡率高的特点。SA-AKI发病机制复杂,有与感染相关的直接机制,也有脓毒症治疗不良结局所驱动的间接机制。一旦诊断为SA-AKI,及时启动适当的支持措施、限制对肾脏的进一步损害至关重要,如抗感染治疗、液体复苏、血管加压药治疗及肾脏替代治疗等。不断有学者致力于探索最佳治疗方案,新型治疗药物、靶向治疗及中药治疗在减少SA-AKI的短期和长期影响方面具有巨大潜力。本文就SA-AKI相关治疗进展作一综述。
Abstract:Sepsis-associated acute kidney injury(SA-AKI)is a common critical illness in hospitalized patients,characterized by high incidence,high mortality. The pathogenesis of SA - AKI is complex,with both direct mechanisms related to infection and indirect mechanisms driven by adverse treatment outcomes in sepsis. Once a diagnosis of SA-AKI is made,it is crucial to initiate appropriate support measures in time to limit further damage to the kidney,such as anti - infective therapy,fluid resuscitation,vasopressor therapy,and renal replacement therapy. There are many scholars committed to exploring the best treatment plan. Promising strategies,including new therapeutic drugs,targeted therapy and Chinese medicine therapy,hold significant potential for mitigating both the short-and long-term consequences of SA-AKI. This article provides a review on the progress in SA-AKI treatment.
文章编号:     中图分类号:R631    文献标志码:A
基金项目:山西省重点研发计划项目(202302130501011)
附件
引用文本:
梁馨月,周芸.脓毒症相关急性肾损伤的治疗进展[J].中国临床研究,2025,38(11):1634-1638,1642.

用微信扫一扫

用微信扫一扫